PRNewsWire
01 Jun 2026, 18:40 UTC · 2h ago
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Search tags
PRNewsWire
01 Jun 2026, 18:40 UTC · 2h ago
Search tags
Story key points
2 claims · impact-rated
A federal securities lawsuit alleges that Vistagen ignored Phase 2 data and published research showing high placebo responses and measurement noise in public speaking challenge endpoints while promoting the PALISADE-3 trial as likely to succeed. — Claims that a biotech firm ignored negative data to overstate the likelihood of success for a Phase 3 trial directly threaten the perceived value of its lead pipeline candidate.
-0.80Kuehn Law is investigating whether Vistagen Therapeutics (VTGN) officers and directors breached fiduciary duties by misrepresenting the risks of Social Anxiety Disorder clinical trials. — Allegations of fiduciary breach and failure to disclose trial risks create significant legal risk and uncertainty regarding company leadership.
-0.60Ticker attribution
Model heads
Continue reading
6 related stories
The company is the subject of a shareholder litigation investigation by Kuehn Law.
The company is the subject of a shareholder litigation investigation by Kuehn Law.
The company is facing a shareholder litigation investigation regarding alleged breaches of fiduciary duties and misrepresentations of clinical trial risks.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
1h ago
